Table 2:
Outcomes
| West (n=210) | East (n=164) | P-value | |
|---|---|---|---|
| Estimated blood loss, mL, median (IQR) | 1150 (600–2225) | 1795 (1302–2654) | < 0.001 |
| Margin, R0, n (%) | 164 (78) | 135 (82) | 0.363 |
|
Final pathology,
n (%)
Perihilar cholangiocarcinoma Other malignancy IPNB Benign |
184 (88) 10 (5) 8 (4) 8 (4) |
155 (95) 9 (6) 0 (0) 0 (0) |
0.004 |
|
Harvested lymph nodes,
median (IQR)
Total Tumor positive |
5 (3–7) 0 (0–1) |
12 (9–16) 0 (0–2) |
< 0.001 0.012 |
| Tumor size, cm, median (IQR) | 3.0 (1.9–4.0) | 2.5 (2.0–3.5) | 0.390 |
| Perineural invasion, n (%) | 113 (66) | 116 (82) | < 0.001 |
| Lymfvascular invasion, n (%) | 50 (29) | 61 (43) | <0.001 |
|
AJCC 7th
edition stage
(PHC only)
0 I II IIIA IIIB IVA IVB |
(n=181)
14 (8) 8 (4) 59 (33) 21 (12) 46 (25) 29 (16) 4 (2) |
(n=131)
1 (1) 9 (7) 45 (34) 8 (6) 38 (29) 24 (18) 6 (5) |
0.043 |
| Morbidity, Dindo grade III or higher, n (%) | 113 (54) | 79 (48) | 0.297 |
| Liver failure, ISGLS grade B/C, n (%) | 43 (21) | 43 (26) | 0.217 |
|
Biliary leakage, ISGLS grade B/C, n (%)
Grade A Grade B Grade C |
79 (38) 18 (7) 72 (34) 7 (3) |
30 (18) 6 (4) 28 (17) 2 (1) |
< 0.001 |
| Hemorrhage, ISGLS grade B/C, n (%) | 14 (7) | 23 (14) | 0.023 |
| 90-day mortality | 28 (13) | 12 (7) | 0.066 |